scholarly journals Histamine antagonist Bepotastine suppresses nasal symptoms caused by Japanese cedar and cypress pollen exposure

2016 ◽  
Vol 5 (1) ◽  
pp. 15-23 ◽  
Author(s):  
Sho Kanzaki ◽  
Kazuhiro Hashiguchi ◽  
Ken-ichiro Wakabayashi ◽  
Kiyochika Suematsu ◽  
Kimihiro Okubo
Keyword(s):  
Japanese Cedar ◽  
Nasal Symptoms ◽  
Pollen Exposure ◽  
Histamine Antagonist

Bepotastine besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO Chamber)

2009 ◽  
Vol 10 (4) ◽  
pp. 523-529 ◽  
Author(s):  
Kazuhiro Hashiguchi ◽  
Huaipeng Tang ◽  
Toshio Fujita ◽  
Kiyochika Suematsu ◽  
Minoru Gotoh ◽  
...  
Keyword(s):  
Japanese Cedar ◽  
Exposure Chamber ◽  
Nasal Symptoms ◽  
Pollen Exposure ◽  
Japanese Cedar Pollen ◽  
Cedar Pollen

scholarly journals Latent 1,3-β-D-glucan acts as an adjuvant for allergen-specific IgE production induced by Japanese cedar pollen exposure

2021 ◽  
Vol 70 (1) ◽  
pp. 105-113
Author(s):  
Takashi Kanno ◽  
Yoshiyuki Adachi ◽  
Katsuyo Ohashi-Doi ◽  
Hiroki Matsuhara ◽  
Rie Hiratsuka ◽  
...  
Keyword(s):  
Japanese Cedar ◽  
Specific Ige ◽  
Pollen Exposure ◽  
Japanese Cedar Pollen ◽  
Cedar Pollen

Persistent nasal symptoms and mediator release after continuous pollen exposure in an environmental challenge chamber

2016 ◽  
Vol 117 (2) ◽  
pp. 150-157 ◽  
Author(s):  
Yusuke Okuma ◽  
Yoshitaka Okamoto ◽  
Syuji Yonekura ◽  
Tomohisa Iinuma ◽  
Toshioki Sakurai ◽  
...  
Keyword(s):  
Mediator Release ◽  
Nasal Symptoms ◽  
Pollen Exposure ◽  
Environmental Challenge

scholarly journals Evaluation of Montelukast for the Treatment of Children With Japanese Cedar Pollinosis Using an Artificial Exposure Chamber (OHIO Chamber)

2018 ◽  
Vol 9 ◽  
pp. 215265671878359 ◽  
Author(s):  
Kazuhiro Hashiguchi ◽  
Kimihiro Okubo ◽  
Yoichi Inoue ◽  
Hirotaka Numaguchi ◽  
Kumi Tanaka ◽  
...  
Keyword(s):  
Day Treatment ◽  
Nasal Congestion ◽  
Placebo Response ◽  
Japanese Cedar ◽  
Nasal Symptom ◽  
Exposure Chamber ◽  
Nasal Discharge ◽  
Japanese Children ◽  
Double Blind ◽  
Pollen Exposure

Background This study evaluated the efficacy of montelukast in reducing seasonal allergic rhinitis symptoms in Japanese children with Japanese cedar (JC) pollinosis induced in an artificial exposure chamber (OHIO Chamber). Methods Pediatric patients aged 10 to 15 years sensitive to JC pollen entered a randomized, double-blind, single-site, crossover study. After confirmation of an allergic response to a JC pollen exposure for 3 hours in the OHIO Chamber during the screening period, subjects received either montelukast 5 mg chewable tablets or placebo for a 7-day treatment period, followed by a 3-hour pollen exposure in the chamber. After a 7-day washout period, subjects crossed over to the other treatment. Subjects were instructed to self-assess their nasal symptoms using 5-point scale for every 30 minutes. The primary end point was the change from baseline (just before entering the exposure chamber for each exposure) in total nasal symptom score (TNSS; the sum of nasal congestion, nasal discharge, and sneezing scores) over 3 hours of pollen exposure. Adverse events (AEs) were evaluated throughout the study. Results A total of 220 subjects (median age, 12 years) received treatment. For TNSS, the between-group difference in the change (95% confidence interval) was −0.01 (−0.11 to 0.10); the change between placebo and montelukast 5 mg was not significant. TNSS in the screening and treatment periods after receiving placebo for 7 days was 1.58 and 1.31, respectively, suggesting a placebo response. On account of high placebo response, a post hoc analysis was conducted. The analysis in a subgroup of subjects who did not show placebo response demonstrated a difference in the efficacy between montelukast and placebo (nominal P < .037). The most common AE was positive urine protein (4.6% with montelukast vs 7.8% with placebo). Conclusions Although montelukast was well tolerated, this study did not demonstrate a treatment difference between active drug and placebo in Japanese children exposed to JC pollen in the OHIO Chamber. Trial Registry: ClinicalTrials.gov, NCT01852812

scholarly journals The Influence of Local Japanese Cedar Pollen Exposure on Allergic Disorders of the Upper Airway.

1999 ◽  
Vol 50 (6) ◽  
pp. 643-647
Author(s):  
Joji Ishii ◽  
Kensei Naito ◽  
Sho Miyata ◽  
Yoshio Senoh ◽  
Naoki Yokoyama ◽  
...  
Keyword(s):  
Upper Airway ◽  
Japanese Cedar ◽  
Pollen Exposure ◽  
Japanese Cedar Pollen ◽  
Cedar Pollen ◽  
Allergic Disorders

Nasal Symptoms Reduction and Decreased Neutrophilia in Japanese Cedar Pollinosis With Prophylactic Treatment With a Combination of Montelukast, Fexofenadine, and Fluticasone Nasal Spray

2019 ◽  
Vol 33 (4) ◽  
pp. 369-377 ◽  
Author(s):  
Hirokuni Otsuka ◽  
Kuninori Otsuka ◽  
Shoji Matsune ◽  
Kimihiro Okubo
Keyword(s):  
Mast Cells ◽  
Nasal Spray ◽  
Symptom Relief ◽  
Japanese Cedar ◽  
Nasal Symptom ◽  
Treatment Protocols ◽  
Nasal Symptoms ◽  
Nasal Swabs ◽  
Before And After ◽  
Japanese Cedar Pollinosis

Background and Objective We reported neutrophil-associated tissue damage in cedar pollinosis subjects with refractory nasal symptoms prior to pollinosis season. Because the leukotriene receptor antagonist, montelukast, can inhibit neutrophil recruitment and activation, we investigated its effects on symptom relief and nasal neutrophilia in pollinosis subjects in the preseason. Methods In the pollinosis preseason, symptomatic (PreSyP, n = 149) and asymptomatic subjects (PreAsP, n = 145) were prophylactically treated, and in season symptomatic subjects (InSyP, n = 134) were treated. Individuals were assigned to 1 of 2 treatment protocols: administration of cetirizine and fluticasone nasal spray (Cet-Flu) or montelukast, fexofenadine, and fluticasone nasal spray (Mo-Fex-Flu). Differences in symptom relief and inflammatory cell infiltration in nasal swabs were investigated. Results In pollen season, 59% of PreSyP subjects given Cet-Flu and 88% of those treated with Mo-Fex-Flu had none or mild symptoms ( P < .00001). In PreAsP subjects in season, 71% of Cet-Flu and 98% of Mo-Fex-Flu recipients had none to mild symptoms ( P < .0000001). The proportions of subjects in the PreSyP group with nasal swabs with neutrophils 1+ to 3+ before and after treatment by Mo-Fex-Flu were 59% and 18%, respectively ( P < .0001), and in PreAsyP, subjects with neutrophils 2+ to 3+ were 17% and 5%, respectively ( P = .034). In PreSyP, a significant reduction in the percentage of subjects with mast cells >1+ was seen following both Cet-Flu ( P = .027) and Mo-Fex-Flu ( P = .0014) treatments. Conclusion In PreSyP and PreAsP subjects, treatments with Mo-Fex-Flu were more effective than Cet-Flu to reduce nasal symptom scores. These effects were associated with reduction in the number of neutrophils and mast cells in nasal swabs.

scholarly journals Longitudinal study of effects of oral dosage ofBifidobacterium bifidumG9-1 on Japanese cedar pollen-induced allergic nasal symptoms in guinea pigs

2015 ◽  
Vol 59 (11) ◽  
pp. 690-699 ◽  
Author(s):  
Satoru Tsunemine ◽  
Yasuhiro Isa ◽  
Hiroshi Ohno ◽  
Satoko Hagino ◽  
Hideki Yamamura ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Guinea Pigs ◽  
Japanese Cedar ◽  
Oral Dosage ◽  
Nasal Symptoms ◽  
Japanese Cedar Pollen ◽  
Cedar Pollen
Sign in / Sign up

Export Citation Format

Share Document